Matches in Wikidata for { <http://www.wikidata.org/entity/Q44451235> ?p ?o ?g. }
- Q44451235 description "2003 nî lūn-bûn" @default.
- Q44451235 description "2003年の論文" @default.
- Q44451235 description "2003年学术文章" @default.
- Q44451235 description "2003年学术文章" @default.
- Q44451235 description "2003年学术文章" @default.
- Q44451235 description "2003年学术文章" @default.
- Q44451235 description "2003年学术文章" @default.
- Q44451235 description "2003年学术文章" @default.
- Q44451235 description "2003年學術文章" @default.
- Q44451235 description "2003年學術文章" @default.
- Q44451235 description "2003年學術文章" @default.
- Q44451235 description "2003年學術文章" @default.
- Q44451235 description "2003年學術文章" @default.
- Q44451235 description "2003년 논문" @default.
- Q44451235 description "article científic" @default.
- Q44451235 description "article scientific" @default.
- Q44451235 description "article scientifique" @default.
- Q44451235 description "articol științific" @default.
- Q44451235 description "articolo scientifico" @default.
- Q44451235 description "artigo científico" @default.
- Q44451235 description "artigo científico" @default.
- Q44451235 description "artigo científico" @default.
- Q44451235 description "artikel ilmiah" @default.
- Q44451235 description "artikull shkencor" @default.
- Q44451235 description "artikulong pang-agham" @default.
- Q44451235 description "artykuł naukowy" @default.
- Q44451235 description "artículo científico publicado en 2003" @default.
- Q44451235 description "artículu científicu" @default.
- Q44451235 description "bilimsel makale" @default.
- Q44451235 description "bài báo khoa học" @default.
- Q44451235 description "naučni članak" @default.
- Q44451235 description "scienca artikolo" @default.
- Q44451235 description "scientific article published in June 2003" @default.
- Q44451235 description "scientific article published in June 2003" @default.
- Q44451235 description "scientific article published in June 2003" @default.
- Q44451235 description "teaduslik artikkel" @default.
- Q44451235 description "tieteellinen artikkeli" @default.
- Q44451235 description "tudományos cikk" @default.
- Q44451235 description "vedecký článok" @default.
- Q44451235 description "vetenskaplig artikel" @default.
- Q44451235 description "videnskabelig artikel" @default.
- Q44451235 description "vitenskapelig artikkel" @default.
- Q44451235 description "vitskapeleg artikkel" @default.
- Q44451235 description "vědecký článek" @default.
- Q44451235 description "wetenschappelijk artikel" @default.
- Q44451235 description "wissenschaftlicher Artikel" @default.
- Q44451235 description "επιστημονικό άρθρο" @default.
- Q44451235 description "мақолаи илмӣ" @default.
- Q44451235 description "наукова стаття, опублікована в червні 2003" @default.
- Q44451235 description "научна статия" @default.
- Q44451235 description "научная статья" @default.
- Q44451235 description "научни чланак" @default.
- Q44451235 description "научни чланак" @default.
- Q44451235 description "מאמר מדעי" @default.
- Q44451235 description "مقالة علمية نشرت في يونيو 2003" @default.
- Q44451235 description "জুন ২০০৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q44451235 description "บทความทางวิทยาศาสตร์" @default.
- Q44451235 description "სამეცნიერო სტატია" @default.
- Q44451235 name "An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer." @default.
- Q44451235 name "An EORTC phase I study of capecitabine" @default.
- Q44451235 type Item @default.
- Q44451235 label "An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer." @default.
- Q44451235 label "An EORTC phase I study of capecitabine" @default.
- Q44451235 prefLabel "An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer." @default.
- Q44451235 prefLabel "An EORTC phase I study of capecitabine" @default.
- Q44451235 P1433 Q44451235-897E084F-E19A-4EE7-9D20-0C8EEDAD71BC @default.
- Q44451235 P1476 Q44451235-AAF754BA-3C85-4070-9A6A-596515803B5A @default.
- Q44451235 P2093 Q44451235-1AC94284-3353-49B1-BA88-AE0C2FEE4D8A @default.
- Q44451235 P2093 Q44451235-3766CD57-F860-417A-9CD4-758C9194A563 @default.
- Q44451235 P2093 Q44451235-6BFE10E0-574E-4EB0-9584-F8BF55A954E1 @default.
- Q44451235 P2093 Q44451235-8AD90FD5-739F-4697-A020-F1A6BDC97728 @default.
- Q44451235 P2093 Q44451235-986A49BB-575D-4495-A728-80316C8D64C9 @default.
- Q44451235 P2093 Q44451235-B0BE04D3-6A49-4B52-9467-5FFA03B41CF9 @default.
- Q44451235 P2860 Q44451235-146EC170-9F01-4657-93B0-AC6D051D18A0 @default.
- Q44451235 P2860 Q44451235-29FCD57A-B04D-41B3-A70F-A08510C0B602 @default.
- Q44451235 P2860 Q44451235-340C00FC-2F07-4609-8470-6F06041D45B9 @default.
- Q44451235 P2860 Q44451235-3B933BBA-1EC7-4925-90B6-65591DBAD0F7 @default.
- Q44451235 P2860 Q44451235-4F0576A4-A9A1-45E2-B13A-76E7ADC3BE47 @default.
- Q44451235 P2860 Q44451235-7A1A23CC-5CA2-4C8B-BC92-339654604240 @default.
- Q44451235 P2860 Q44451235-A2C05DF6-C96A-4848-9D38-C9E2391C5FDD @default.
- Q44451235 P2860 Q44451235-C0D47733-F353-4928-B56E-E9BD28BB2C20 @default.
- Q44451235 P2860 Q44451235-C3DEA635-CD84-46F1-B43F-D61B9EDDF47F @default.
- Q44451235 P2860 Q44451235-C9A74E30-3497-487F-8241-A715FD701F99 @default.
- Q44451235 P2860 Q44451235-CB954362-C570-4543-8C6D-1DCD094B7141 @default.
- Q44451235 P2860 Q44451235-E0FE7B23-0FC3-45F2-8052-719D03395538 @default.
- Q44451235 P2860 Q44451235-FBB154EF-E1BE-4149-8CBB-1B713A8EC589 @default.
- Q44451235 P304 Q44451235-3EA3DD2E-3E03-44DC-A6AD-09052D9042EF @default.
- Q44451235 P31 Q44451235-29F1451F-CE77-4849-9707-4094408A49C2 @default.
- Q44451235 P356 Q44451235-CE9B5A31-DA74-4770-BCD6-EEF0E8E21413 @default.
- Q44451235 P433 Q44451235-7BFE6A3E-F63B-4C99-A871-0E5B014C5655 @default.
- Q44451235 P478 Q44451235-C9AF079D-6F54-4FCA-9FFB-3A7D77F15C46 @default.
- Q44451235 P50 Q44451235-AF2F2CC0-76F0-405D-8783-E88234043DA7 @default.
- Q44451235 P577 Q44451235-19AFF71F-8181-41A6-A233-EA01CD5479FF @default.
- Q44451235 P698 Q44451235-9CB7BA74-E6AF-4F4F-A865-340328E60C14 @default.
- Q44451235 P921 Q44451235-FB229B03-DB87-4335-8802-C4E0CC29B12C @default.
- Q44451235 P356 S0959-8049(03)00266-1 @default.
- Q44451235 P698 12763217 @default.
- Q44451235 P1433 Q332260 @default.
- Q44451235 P1476 "An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer" @default.
- Q44451235 P2093 "G Atalay" @default.